

**Appendix Table F51. Clinical outcomes after oxybutynin treatments (individual RCTs)**

Reference	Active drug	Dose	Control drug	Dose	Active events/ randomized	Control events/ randomized	Relative risk (95% CI)	Absolute risk difference (95% CI)	Number needed to treat (95% CI)	Attributable events (95% CI)
<b>Continence</b>										
Davila, 2001 <sup>271</sup>	Oxybutynin transdermal	1.3mg	Oxybutynin- immediate release	5mg twice/thrice daily or 7.5mg thrice daily	8/38	10/38	0.80 (0.35; 1.81)	-0.05 (-0.24; 0.14)		
Anderson, 1999 <sup>391</sup>	CR- oxybutynin	5 to 30mg once daily	IR-oxybutynin	5mg 1 to 4 times daily	4/53	7/52	0.56 (0.17; 1.80)	-0.06 (-0.18; 0.06)		
Anderson, 1999 <sup>391</sup>	CR- oxybutynin	5 to 30mg once daily	IR-oxybutynin	5mg 1 to 4 times daily	4/53	5/52	0.78 (0.22; 2.76)	-0.02 (-0.13; 0.09)		
Anderson, 1999 <sup>391</sup>	CR- oxybutynin	5 to 30mg once daily	IR-oxybutynin	5mg 1 to 4 times daily	2/53	3/52	0.65 (0.11; 3.76)	-0.02 (-0.10; 0.06)		
<b>Adverse events</b>										
Anderson, 1999 <sup>391</sup>	CR- oxybutynin	5 to 30mg once daily	IR-oxybutynin	5mg 1 to 4 times daily	22/53	21/52	1.03 (0.65; 1.63)	0.01 (-0.18; 0.20)		
Anderson, 1999 <sup>391</sup>	CR- oxybutynin	5 to 30mg once daily	IR-oxybutynin	5mg 1 to 4 times daily	22/53	21/52	1.03 (0.65; 1.63)	0.01 (-0.18; 0.20)		
<b>Continence</b>										
Anderson, 1999 <sup>391</sup>	CR- oxybutynin	5 to 30mg once daily	IR-oxybutynin	5mg 1 to 4 times daily	6/53	4/52	1.47 (0.44; 4.92)	0.04 (-0.08; 0.15)		
<b>Efficacy</b>										
Corcos, 2006 <sup>270</sup>	Oxybutynin- controlled release	5mg/day	Oxybutynin- controlled release	10mg/day	22/77	26/77	0.85 (0.53; 1.36)	-0.05 (-0.20; 0.09)		
Corcos, 2006 <sup>270</sup>	Oxybutynin- controlled release	5mg/day	Oxybutynin- controlled release	10mg/day	27/77	28/77	0.96 (0.63; 1.47)	-0.01 (-0.16; 0.14)		
Corcos, 2006 <sup>270</sup>	Oxybutynin- controlled release	5mg/day	Oxybutynin- controlled release	10mg/day	71/77	61/77	1.16 (1.02; 1.33)	0.13 (0.02; 0.24)	8 (4; 47)	130 (21; 238)
Corcos, 2006 <sup>270</sup>	Oxybutynin- controlled release	5mg/day	Oxybutynin- controlled release	15mg/day	22/77	42/83	0.56 (0.37; 0.85)	-0.22 (-0.37; -0.07)	-5 (-14; -3)	-220 (-368; -73)
Corcos, 2006 <sup>270</sup>	Oxybutynin- controlled release	5mg/day	Oxybutynin- controlled release	15mg/day	27/77	43/83	0.68 (0.47; 0.98)	-0.17 (-0.32; -0.02)	-6 (-62; -3)	-167 (-319; -16)

**Appendix Table F51. Clinical outcomes after oxybutynin treatments (individual RCTs) (continued)**

Reference	Active drug	Dose	Control drug	Dose	Active events/ randomized	Control events/ randomized	Relative risk (95% CI)	Absolute risk difference (95% CI)	Number needed to treat (95% CI)	Attributable events (95% CI)
Corcos, 2006 <sup>270</sup>	Oxybutynin- controlled release	5mg/day	Oxybutynin- controlled release	15mg/day	71/77	68/83	1.13 (1.00; 1.27)	0.10 (0.00; 0.20)	10 (5; 1567)	103 (1; 205)
Corcos, 2006 <sup>270</sup>	Oxybutynin- controlled release	10mg/day	Oxybutynin- controlled release	15mg/day	26/77	42/83	0.67 (0.46; 0.97)	-0.17 (-0.32; -0.02)	-6 (-57; -3)	-168 (-319; -18)
Corcos, 2006 <sup>270</sup>	Oxybutynin- controlled release	10mg/day	Oxybutynin- controlled release	15mg/day	28/77	43/83	0.70 (0.49; 1.01)	-0.15 (-0.31; 0.00)	-6 (-408; -3)	-154 (-306; -2)
Corcos, 2006 <sup>270</sup>	Oxybutynin- controlled release	10mg/day	Oxybutynin- controlled release	15mg/day	61/77	68/83	0.97 (0.83; 1.13)	-0.03 (-0.15; 0.10)		
<b>Adverse effects</b>										
Davila, 2001 <sup>271</sup>	Oxybutynin transdermal	1.3mg	Oxybutynin- immediate release	5mg twice/thrice daily or 7.5mg thrice daily	25/38	13/38	1.92 (1.17; 3.16)	0.32 (0.10; 0.53)	3 (2; 10)	316 (102; 529)
Gupta, 1999 <sup>296</sup>	OROS oxybutynin chloride	5mg once daily	Immediate- release oxybutynin- Ditropan	5mg thrice daily	6/13	12/13	0.50 (0.27; 0.92)	-0.46 (-0.77; -0.15)	-2 (-6; -1)	-462 (-769; -154)
<b>Undefined</b>										
Salvatore, 2005 <sup>371</sup>	Oxybutynin	2.5 twice daily	Oxybutynin	5mg nocte	3/27	4/39	1.08 (0.26; 4.46)	0.01 (-0.14; 0.16)		
<b>Adverse effects</b>										
Davila, 2001 <sup>271</sup>	Oxybutynin transdermal	1.3mg	Oxybutynin- immediate release	5mg twice/thrice daily or 7.5mg thrice daily	14/38	2/38	7.00 (1.71; 28.72)	0.32 (0.15; 0.48)	3 (2; 7)	316 (147; 485)
Anderson, 1999 <sup>391</sup>	CR- oxybutynin	5 to 30mg once daily	IR-oxybutynin	5mg 1 to 4 times daily	46/53	49/52	0.92 (0.81; 1.04)	-0.07 (-0.19; 0.04)		
Anderson, 1999 <sup>391</sup>	CR- oxybutynin	5 to 30mg once daily	IR-oxybutynin	5mg 1 to 4 times daily	46/53	49/52	0.92 (0.81; 1.04)	-0.07 (-0.19; 0.04)		

**Appendix Table F51. Clinical outcomes after oxybutynin treatments (individual RCTs) (continued)**

Reference	Active drug	Dose	Control drug	Dose	Active events/ randomized	Control events/ randomized	Relative risk (95% CI)	Absolute risk difference (95% CI)	Number needed to treat (95% CI)	Attributable events (95% CI)
<b>Discontinuation</b>										
Preik, 2004 <sup>392</sup>	OROS-oxybutynin controlled release	5-30mg/day	immediate-release oxybutynin	5-20mg/day	5/53	5/52	0.98 (0.30; 3.19)	0.00 (-0.11; 0.11)		
<b>Withdrawal</b>										
Corcos, 2006 <sup>270</sup>	Oxybutynin-controlled release	5mg/day	Oxybutynin-controlled release	10mg/day	3/77	11/77	0.27 (0.08; 0.94)	-0.10 (-0.19; -0.01)	-10 (-69; -5)	-104 (-193; -15)
Corcos, 2006 <sup>270</sup>	Oxybutynin-controlled release	5mg/day	Oxybutynin-controlled release	10mg/day	4/77	4/77	1.00 (0.26; 3.86)	0.00 (-0.07; 0.07)		
Corcos, 2006 <sup>270</sup>	Oxybutynin-controlled release	5mg/day	Oxybutynin-controlled release	15mg/day	3/77	12/83	0.27 (0.08; 0.92)	-0.11 (-0.19; -0.02)	-9 (-54; -5)	-106 (-193; -18)
Corcos, 2006 <sup>270</sup>	Oxybutynin-controlled release	10mg/day	Oxybutynin-controlled release	15mg/day	11/77	12/83	0.99 (0.46; 2.11)	0.00 (-0.11; 0.11)		
Corcos, 2006 <sup>270</sup>	Oxybutynin-controlled release	5mg/day	Oxybutynin-controlled release	15mg/day	4/77	2/83	2.16 (0.41; 11.44)	0.03 (-0.03; 0.09)		
Corcos, 2006 <sup>270</sup>	Oxybutynin-controlled release	10mg/day	Oxybutynin-controlled release	15mg/day	4/77	2/83	2.16 (0.41; 11.44)	0.03 (-0.03; 0.09)		
<b>Blurred vision</b>										
Corcos, 2006 <sup>270</sup>	Oxybutynin-controlled release	5mg/day	Oxybutynin-controlled release	10mg/day	1/77	1/77	1.00 (0.06; 15.70)	0.00 (-0.04; 0.04)		
Corcos, 2006 <sup>270</sup>	Oxybutynin-controlled release	5mg/day	Oxybutynin-controlled release	15mg/day	1/77	1/83	1.08 (0.07; 16.94)	0.00 (-0.03; 0.04)		
Corcos, 2006 <sup>270</sup>	Oxybutynin-controlled release	10mg/day	Oxybutynin-controlled release	15mg/day	1/77	1/83	1.08 (0.07; 16.94)	0.00 (-0.03; 0.04)		

**Appendix Table F51. Clinical outcomes after oxybutynin treatments (individual RCTs) (continued)**

Reference	Active drug	Dose	Control drug	Dose	Active events/ randomized	Control events/ randomized	Relative risk (95% CI)	Absolute risk difference (95% CI)	Number needed to treat (95% CI)	Attributable events (95% CI)
Davila, 2001 <sup>271</sup>	Oxybutynin transdermal	1.3mg	Oxybutynin- immediate release	5mg twice/thrice daily or 7.5mg thrice daily	7/38	9/38	0.78 (0.32; 1.87)	-0.05 (-0.24; 0.13)		
Anderson, 1999 <sup>391</sup>	CR- oxybutynin	5 to 30mg once daily	IR-oxybutynin	5mg 1 to 4 times daily	15/53	9/52	1.64 (0.79; 3.40)	0.11 (-0.05; 0.27)		
Anderson, 1999 <sup>391</sup>	CR- oxybutynin	5 to 30mg once daily	IR-oxybutynin	5mg 1 to 4 times daily	15/53	9/52	1.64 (0.79; 3.40)	0.11 (-0.05; 0.27)		
<b>Treatment compliance</b>										
Salvatore, 2005 <sup>371</sup>	Oxybutynin	2.5 twice daily	Oxybutynin	5mg nocte	11/27	11/39	1.44 (0.73; 2.84)	0.13 (-0.11; 0.36)		
<b>Constipation</b>										
Dmochowski, 2002 <sup>276</sup>	Oxybutynin TDS	1.3mg	Oxybutynin TDS	2.6mg	7/130	3/133	2.39 (0.63; 9.03)	0.03 (-0.01; 0.08)		
Dmochowski, 2002 <sup>276</sup>	Oxybutynin TDS	1.3mg	Oxybutynin TDS	3.9mg	7/130	1/125	6.73 (0.84; 53.92)	0.05 (0.00; 0.09)	22 (11; 249)	46 (4; 88)
Dmochowski, 2002 <sup>276</sup>	Oxybutynin TDS	2.6mg	Oxybutynin TDS	3.9mg	3/133	1/125	2.82 (0.30; 26.75)	0.01 (-0.02; 0.04)		
Dmochowski, 2002 <sup>276</sup>	Oxybutynin- controlled release	5mg/day	Oxybutynin- controlled release	10mg/day	4/77	3/77	1.33 (0.31; 5.76)	0.01 (-0.05; 0.08)		
Dmochowski, 2002 <sup>276</sup>	Oxybutynin- controlled release	5mg/day	Oxybutynin- controlled release	15mg/day	4/77	4/83	1.08 (0.28; 4.16)	0.00 (-0.06; 0.07)		
Dmochowski, 2002 <sup>276</sup>	Oxybutynin- controlled release	10mg/day	Oxybutynin- controlled release	15mg/day	3/77	4/83	0.81 (0.19; 3.50)	-0.01 (-0.07; 0.05)		
Dmochowski, 2002 <sup>276</sup>	Oxybutynin transdermal	1.3mg	Oxybutynin- immediate release	5mg twice/thrice daily or 7.5mg thrice daily	8/38	19/38	0.42 (0.21; 0.84)	-0.29 (-0.49; -0.08)	-3 (-12; -2)	-289 (-495; -84)
Dmochowski, 2002 <sup>276</sup>	CR- oxybutynin	5 to 30mg once daily	IR-oxybutynin	5mg 1 to 4 times daily	16/53	16/52	0.98 (0.55; 1.75)	-0.01 (-0.18; 0.17)		
<b>Constipation</b>										
Anderson, 1999 <sup>391</sup>	CR- oxybutynin	5 to 30mg once daily	IR-oxybutynin	5mg 1 to 4 times daily	16/53	16/52	0.98 (0.55; 1.75)	-0.01 (-0.18; 0.17)		

**Appendix Table F51. Clinical outcomes after oxybutynin treatments (individual RCTs) (continued)**

Reference	Active drug	Dose	Control drug	Dose	Active events/ randomized	Control events/ randomized	Relative risk (95% CI)	Absolute risk difference (95% CI)	Number needed to treat (95% CI)	Attributable events (95% CI)
<b>Dizziness</b>										
Dmochowski, 2002 <sup>276</sup>	Oxybutynin TDS	1.3mg	Oxybutynin TDS	3.9mg	2/130	5/125	0.38 (0.08; 1.95)	-0.02 (-0.06; 0.02)		
Dmochowski, 2002 <sup>276</sup>	Oxybutynin TDS	2.6mg	Oxybutynin TDS	3.9mg	4/133	5/125	0.75 (0.21; 2.74)	-0.01 (-0.05; 0.04)		
Salvatore, 2005 <sup>371</sup>	Oxybutynin	2.5 twice daily	Oxybutynin	5mg nocte	0/27	2/39	0.29 (0.01; 5.73)	-0.05 (-0.14; 0.04)		
Corcos, 2006 <sup>270</sup>	Oxybutynin- controlled release	5mg/day	Oxybutynin- controlled release	10mg/day	5/77	6/77	0.83 (0.27; 2.62)	-0.01 (-0.09; 0.07)		
Corcos, 2006 <sup>270</sup>	Oxybutynin- controlled release	5mg/day	Oxybutynin- controlled release	15mg/day	5/77	6/83	0.90 (0.29; 2.82)	-0.01 (-0.09; 0.07)		
Corcos, 2006 <sup>270</sup>	Oxybutynin- controlled release	10mg/day	Oxybutynin- controlled release	15mg/day	6/77	6/83	1.08 (0.36; 3.20)	0.01 (-0.08; 0.09)		
Davila, 2001 <sup>271</sup>	Oxybutynin transdermal	1.3mg	Oxybutynin- immediate release	5mg twice/thrice daily or 7.5mg thrice daily	6/38	10/38	0.60 (0.24; 1.49)	-0.11 (-0.29; 0.08)		
Anderson, 1999 <sup>391</sup>	CR- oxybutynin	5 to 30mg once daily	IR-oxybutynin	5mg 1 to 4 times daily	15/53	20/52	0.74 (0.42; 1.27)	-0.10 (-0.28; 0.08)		
Anderson, 1999 <sup>391</sup>	CR- oxybutynin	5 to 30mg once daily	IR-oxybutynin	5mg 1 to 4 times daily	15/53	20/52	0.74 (0.42; 1.27)	-0.10 (-0.28; 0.08)		
<b>Maximum dosage reached</b>										
Davila, 2001 <sup>271</sup>	Oxybutynin transdermal	1.3mg	Oxybutynin- immediate release	5mg twice/thrice daily or 7.5mg thrice daily	26/38	12/38	2.17 (1.29; 3.63)	0.37 (0.16; 0.58)	3 (2; 6)	368 (159; 577)
<b>Dry eyes</b>										
Salvatore, 2005 <sup>371</sup>	Oxybutynin	2.5 twice daily	Oxybutynin	5mg nocte	0/27	1/39	0.48 (0.02; 11.27)	-0.03 (-0.10; 0.05)		
<b>Worse dry mouth on completion of treatment</b>										
Davila, 2001 <sup>271</sup>	Oxybutynin transdermal	1.3mg	Oxybutynin- immediate release	5mg twice/thrice daily or 7.5mg thrice daily	2/38	13/38	0.15 (0.04; 0.64)	-0.29 (-0.46; -0.12)	-3 (-8; -2)	-289 (-456; -123)

**Appendix Table F51. Clinical outcomes after oxybutynin treatments (individual RCTs) (continued)**

Reference	Active drug	Dose	Control drug	Dose	Active events/ randomized	Control events/ randomized	Relative risk (95% CI)	Absolute risk difference (95% CI)	Number needed to treat (95% CI)	Attributable events (95% CI)
<b>Dry mouth</b>										
Gupta, 1999 <sup>296</sup>	OROS oxybutynin chloride	5mg once daily	Immediate- release oxybutynin- Ditropan	5mg thrice daily	6/13	10/13	0.60 (0.31; 1.16)	-0.31 (-0.66; 0.05)		
Salvatore, 2005 <sup>371</sup>	Oxybutynin	2.5 twice daily	Oxybutynin	5mg nocte	1/27	4/39	0.36 (0.04; 3.06)	-0.07 (-0.18; 0.05)		
<b>Moderate to severe dry mouth</b>										
Versi, 2000 <sup>42</sup>	CR- Oxybutynin	5mg/day	IR-Oxybutynin	5mg/day	4/111	8/115	0.52 (0.16; 1.67)	-0.03 (-0.09; 0.02)		
<b>Dry mouth</b>										
Corcos, 2006 <sup>270</sup>	Oxybutynin- controlled release	5mg/day	Oxybutynin- controlled release	10mg/day	43/77	52/77	0.83 (0.64; 1.06)	-0.12 (-0.27; 0.04)		
<b>Severe dry mouth</b>										
Corcos, 2006 <sup>270</sup>	Oxybutynin- controlled release	5mg/day	Oxybutynin- controlled release	10mg/day	2/77	11/77	0.18 (0.04; 0.79)	-0.12 (-0.20; -0.03)	-9 (-32; -5)	-117 (-203; -31)
<b>Dry mouth</b>										
Corcos, 2006 <sup>270</sup>	Oxybutynin- controlled release	5mg/day	Oxybutynin- controlled release	15mg/day	43/77	58/83	0.80 (0.63; 1.02)	-0.14 (-0.29; 0.01)		
<b>Severe dry mouth</b>										
Corcos, 2006 <sup>270</sup>	Oxybutynin- controlled release	5mg/day	Oxybutynin- controlled release	15mg/day	2/77	4/83	0.54 (0.10; 2.86)	-0.02 (-0.08; 0.04)		
<b>Dry mouth</b>										
Corcos, 2006 <sup>270</sup>	Oxybutynin- controlled release	10mg/day	Oxybutynin- controlled release	15mg/day	52/77	58/83	0.97 (0.78; 1.19)	-0.02 (-0.17; 0.12)		
<b>Severe dry mouth</b>										
Corcos, 2006 <sup>270</sup>	Oxybutynin- controlled release	10mg/day	Oxybutynin- controlled release	15mg/day	11/77	4/83	2.96 (0.99; 8.92)	0.09 (0.00; 0.19)	11 (5; 254)	95 (4; 185)

**Appendix Table F51. Clinical outcomes after oxybutynin treatments (individual RCTs) (continued)**

Reference	Active drug	Dose	Control drug	Dose	Active events/ randomized	Control events/ randomized	Relative risk (95% CI)	Absolute risk difference (95% CI)	Number needed to treat (95% CI)	Attributable events (95% CI)
<b>Dry mouth of any severity</b>										
Preik, 2004 <sup>392</sup>	OROS-oxybutynin controlled release	5-30mg/day	immediate-release oxybutynin	5-20mg/day	31/53	41/52	0.74 (0.57; 0.97)	-0.20 (-0.38; -0.03)	-5 (-33; -3)	-204 (-377; -31)
<b>Moderate or severe dry mouth</b>										
Preik, 2004 <sup>392</sup>	OROS-oxybutynin controlled release	5-30mg/day	immediate-release oxybutynin	5-20mg/day	12/53	22/52	0.53 (0.29; 0.95)	-0.20 (-0.38; -0.03)	-5 (-37; -3)	-201 (-375; -27)
<b>Dose titration endpoint-MTD-dry mouth</b>										
Preik, 2004 <sup>392</sup>	OROS-oxybutynin controlled release	5-30mg/day	immediate-release oxybutynin	5-20mg/day	7/53	13/52	0.53 (0.23; 1.22)	-0.12 (-0.27; 0.03)		
<b>Dose titration endpoint-MED-dry mouth</b>										
Preik, 2004 <sup>392</sup>	OROS-oxybutynin controlled release	5-30mg/day	immediate-release oxybutynin	5-20mg/day	3/53	7/52	0.42 (0.11; 1.54)	-0.08 (-0.19; 0.03)		
<b>Moderate dry mouth</b>										
Preik, 2004 <sup>392</sup>	OROS-oxybutynin controlled release	5-30mg/day	immediate-release oxybutynin	5-20mg/day	1/53	4/52	0.25 (0.03; 2.12)	-0.06 (-0.14; 0.02)		
<b>Dose titration endpoint-MAD-dry mouth</b>										
Preik, 2004 <sup>392</sup>	OROS-oxybutynin controlled release	5-30mg/day	immediate-release oxybutynin	5-20mg/day	1/53	1/52	0.98 (0.06; 15.28)	0.00 (-0.05; 0.05)		
<b>Moderate to severe dry mouth</b>										
Anderson, 1999 <sup>391</sup>	CR-oxybutynin	5 to 30mg once daily	IR-oxybutynin	5mg 1 to 4 times daily	3/53	11/52	0.27 (0.08; 0.90)	-0.15 (-0.28; -0.03)	-6 (-36; -4)	-155 (-282; -28)
Anderson, 1999 <sup>391</sup>	CR-oxybutynin	5 to 30mg once daily	IR-oxybutynin	5mg 1 to 4 times daily	5/53	10/52	0.49 (0.18; 1.34)	-0.10 (-0.23; 0.03)		
Anderson, 1999 <sup>391</sup>	CR-oxybutynin	5 to 30mg once daily	IR-oxybutynin	5mg 1 to 4 times daily	7/53	10/52	0.69 (0.28; 1.67)	-0.06 (-0.20; 0.08)		

**Appendix Table F51. Clinical outcomes after oxybutynin treatments (individual RCTs) (continued)**

Reference	Active drug	Dose	Control drug	Dose	Active events/ randomized	Control events/ randomized	Relative risk (95% CI)	Absolute risk difference (95% CI)	Number needed to treat (95% CI)	Attributable events (95% CI)
Anderson, 1999 <sup>391</sup>	CR- oxybutynin	5 to 30mg once daily	IR-oxybutynin	5mg 1 to 4 times daily	2/53	4/52	0.49 (0.09; 2.56)	-0.04 (-0.13; 0.05)		
<b>Dry mouth</b>										
Davila, 2001 <sup>271</sup>	Oxybutynin transdermal	1.3mg	Oxybutynin- immediate release	5mg twice/thrice daily or 7.5mg thrice daily	15/38	31/38	0.48 (0.32; 0.74)	-0.42 (-0.62; -0.22)	-2 (-4; -2)	-421 (-619; -223)
Anderson, 1999 <sup>391</sup>	CR- oxybutynin	5 to 30mg once daily	IR-oxybutynin	5mg 1 to 4 times daily	36/53	45/52	0.78 (0.63; 0.97)	-0.19 (-0.34; -0.03)	-5 (-33; -3)	-186 (-342; -30)
Anderson, 1999 <sup>391</sup>	CR- oxybutynin	5 to 30mg once daily	IR-oxybutynin	5mg 1 to 4 times daily	36/53	45/52	0.78 (0.63; 0.97)	-0.19 (-0.34; -0.03)	-5 (-33; -3)	-186 (-342; -30)
<b>Moderate to severe dry mouth</b>										
Anderson, 1999 <sup>391</sup>	CR- oxybutynin	5 to 30mg once daily	IR-oxybutynin	5mg 1 to 4 times daily	13/53	24/52	0.53 (0.30; 0.93)	-0.22 (-0.39; -0.04)	-5 (-26; -3)	-216 (-395; -38)
Anderson, 1999 <sup>391</sup>	CR- oxybutynin	5 to 30mg once daily	IR-oxybutynin	5mg 1 to 4 times daily	13/53	24/52	0.53 (0.30; 0.93)	-0.22 (-0.39; -0.04)	-5 (-26; -3)	-216 (-395; -38)
<b>Dry nose</b>										
Salvatore, 2005 <sup>371</sup>	Oxybutynin	2.5 twice daily	Oxybutynin	5mg nocte	0/27	1/39	0.48 (0.02; 11.27)	-0.03 (-0.10; 0.05)		
<b>Dry throat</b>										
Salvatore, 2005 <sup>371</sup>	Oxybutynin	2.5 twice daily	Oxybutynin	5mg nocte	2/27	0/39	7.14 (0.36; 143.14)	0.07 (-0.04; 0.19)		
Corcos, 2006 <sup>270</sup>	Oxybutynin- controlled release	5mg/day	Oxybutynin- controlled release	10mg/day	21/77	32/77	0.66 (0.42; 1.03)	-0.14 (-0.29; 0.01)		
Corcos, 2006 <sup>270</sup>	Oxybutynin- controlled release	5mg/day	Oxybutynin- controlled release	15mg/day	21/77	24/83	0.94 (0.57; 1.55)	-0.02 (-0.16; 0.12)		
Corcos, 2006 <sup>270</sup>	Oxybutynin- controlled release	10mg/day	Oxybutynin- controlled release	15mg/day	32/77	24/83	1.44 (0.94; 2.21)	0.13 (-0.02; 0.27)		
<b>Dyspepsia</b>										
Chancellor, 2001 <sup>255</sup>	ER- oxybutynin	10mg/day	IR-oxybutynin	5mg/day	0/36	1/36	0.33 (0.01; 7.92)	-0.03 (-0.10; 0.05)		



**Appendix Table F51. Clinical outcomes after oxybutynin treatments (individual RCTs) (continued)**

Reference	Active drug	Dose	Control drug	Dose	Active events/ randomized	Control events/ randomized	Relative risk (95% CI)	Absolute risk difference (95% CI)	Number needed to treat (95% CI)	Attributable events (95% CI)
<b>Dysuria</b>										
Dmochowski, 2002 <sup>276</sup>	Oxybutynin TDS	1.3mg	Oxybutynin TDS	2.6mg	1/130	3/133	0.34 (0.04; 3.24)	-0.01 (-0.04; 0.01)		
Dmochowski, 2002 <sup>276</sup>	Oxybutynin TDS	1.3mg	Oxybutynin TDS	3.9mg	1/130	3/125	0.32 (0.03; 3.04)	-0.02 (-0.05; 0.01)		
Dmochowski, 2002 <sup>276</sup>	Oxybutynin TDS	2.6mg	Oxybutynin TDS	3.9mg	3/133	3/125	0.94 (0.19; 4.57)	0.00 (-0.04; 0.04)		
<b>Erythema absent</b>										
Dmochowski, 2002 <sup>276</sup>	Oxybutynin TDS	1.3mg	Oxybutynin TDS	2.6mg	120/130	108/133	1.14 (1.03; 1.25)	0.11 (0.03; 0.19)	9 (5; 33)	111 (30; 192)
<b>Erythema-mild</b>										
Dmochowski, 2002 <sup>276</sup>	Oxybutynin TDS	1.3mg	Oxybutynin TDS	2.6mg	79/130	92/133	0.88 (0.73; 1.05)	-0.08 (-0.20; 0.03)		
<b>Erythema-moderate</b>										
Dmochowski, 2002 <sup>276</sup>	Oxybutynin TDS	1.3mg	Oxybutynin TDS	2.6mg	46/130	46/133	1.02 (0.74; 1.42)	0.01 (-0.11; 0.12)		
<b>Erythema-severe</b>										
Dmochowski, 2002 <sup>276</sup>	Oxybutynin TDS	1.3mg	Oxybutynin TDS	2.6mg	6/130	8/133	0.77 (0.27; 2.15)	-0.01 (-0.07; 0.04)		
<b>Halitosis</b>										
Corcos, 2006 <sup>270</sup>	Oxybutynin- controlled release	5mg/day	Oxybutynin- controlled release	10mg/day	6/77	10/77	0.60 (0.23; 1.57)	-0.05 (-0.15; 0.04)		
Corcos, 2006 <sup>270</sup>	Oxybutynin- controlled release	5mg/day	Oxybutynin- controlled release	15mg/day	6/77	8/83	0.81 (0.29; 2.22)	-0.02 (-0.11; 0.07)		
Corcos, 2006 <sup>270</sup>	Oxybutynin- controlled release	10mg/day	Oxybutynin- controlled release	15mg/day	10/77	8/83	1.35 (0.56; 3.24)	0.03 (-0.06; 0.13)		
<b>Headache</b>										
Salvatore, 2005 <sup>371</sup>	Oxybutynin	2.5 twice daily	Oxybutynin	5mg nocte	0/27	1/39	0.48 (0.02; 11.27)	-0.03 (-0.10; 0.05)		
Salvatore, 2005 <sup>371</sup>	Oxybutynin	2.5 twice daily	Oxybutynin	5mg nocte	0/27	1/39	0.48 (0.02; 11.27)	-0.03 (-0.10; 0.05)		
Chancellor, 2001 <sup>255</sup>	ER- oxybutynin	10mg/day	IR-oxybutynin	5mg/day	6/36	6/36	1.00 (0.36; 2.81)	0.00 (-0.17; 0.17)		

**Appendix Table F51. Clinical outcomes after oxybutynin treatments (individual RCTs) (continued)**

Reference	Active drug	Dose	Control drug	Dose	Active events/ randomized	Control events/ randomized	Relative risk (95% CI)	Absolute risk difference (95% CI)	Number needed to treat (95% CI)	Attributable events (95% CI)
<b>Impaired urination</b>										
Anderson, 1999 <sup>391</sup>	CR- oxybutynin	5 to 30mg once daily	IR-oxybutynin	5mg 1 to 4 times daily	13/53	15/52	0.85 (0.45; 1.61)	-0.04 (-0.21; 0.13)		
<b>Nausea</b>										
Dmochowski, 2002 <sup>276</sup>	Oxybutynin TDS	1.3mg	Oxybutynin TDS	2.6mg	6/130	5/133	1.23 (0.38; 3.92)	0.01 (-0.04; 0.06)		
Dmochowski, 2002 <sup>276</sup>	Oxybutynin TDS	1.3mg	Oxybutynin TDS	3.9mg	6/130	2/125	2.88 (0.59; 14.02)	0.03 (-0.01; 0.07)		
Dmochowski, 2002 <sup>276</sup>	Oxybutynin TDS	2.6mg	Oxybutynin TDS	3.9mg	5/133	2/125	2.35 (0.46; 11.89)	0.02 (-0.02; 0.06)		
Salvatore, 2005 <sup>371</sup>	Oxybutynin	2.5 twice daily	Oxybutynin	5mg nocte	0/27	4/39	0.16 (0.01; 2.83)	-0.10 (-0.21; 0.01)		
Corcos, 2006 <sup>270</sup>	Oxybutynin- controlled release	5mg/day	Oxybutynin- controlled release	10mg/day	5/77	8/77	0.63 (0.21; 1.83)	-0.04 (-0.13; 0.05)		
Corcos, 2006 <sup>270</sup>	Oxybutynin- controlled release	5mg/day	Oxybutynin- controlled release	15mg/day	5/77	7/83	0.77 (0.26; 2.32)	-0.02 (-0.10; 0.06)		
Chancellor, 2001 <sup>255</sup>	ER- oxybutynin	10mg/day	IR-oxybutynin	5mg/day	0/36	1/36	0.33 (0.01; 7.92)	-0.03 (-0.10; 0.05)		
Corcos, 2006 <sup>270</sup>	Oxybutynin- controlled release	10mg/day	Oxybutynin- controlled release	15mg/day	8/77	7/83	1.23 (0.47; 3.24)	0.02 (-0.07; 0.11)		
Davila, 2001 <sup>271</sup>	Oxybutynin transdermal	1.3mg	Oxybutynin- immediate release	5mg twice/thrice daily or 7.5mg thrice daily	3/38	10/38	0.30 (0.09; 1.01)	-0.18 (-0.35; -0.02)	-5 (-50; -3)	-184 (-348; -20)
Anderson, 1999 <sup>391</sup>	CR- oxybutynin	5 to 30mg once daily	IR-oxybutynin	5mg 1 to 4 times daily	10/53	9/52	1.09 (0.48; 2.46)	0.02 (-0.13; 0.16)		
Anderson, 1999 <sup>391</sup>	CR- oxybutynin	5 to 30mg once daily	IR-oxybutynin	5mg 1 to 4 times daily	10/53	9/52	1.09 (0.48; 2.46)	0.02 (-0.13; 0.16)		
<b>Nervousness</b>										
Anderson, 1999 <sup>391</sup>	CR- oxybutynin	5 to 30mg once daily	IR-oxybutynin	5mg 1 to 4 times daily	13/53	12/52	1.06 (0.54; 2.11)	0.01 (-0.15; 0.18)		
Anderson, 1999 <sup>391</sup>	CR- oxybutynin	5 to 30mg once daily	IR-oxybutynin	5mg 1 to 4 times daily	13/53	12/52	1.06 (0.54; 2.11)	0.01 (-0.15; 0.18)		

**Appendix Table F51. Clinical outcomes after oxybutynin treatments (individual RCTs) (continued)**

Reference	Active drug	Dose	Control drug	Dose	Active events/ randomized	Control events/ randomized	Relative risk (95% CI)	Absolute risk difference (95% CI)	Number needed to treat (95% CI)	Attributable events (95% CI)
<b>Palpitation</b>										
Davila, 2001 <sup>271</sup>	Oxybutynin transdermal	1.3mg	Oxybutynin- immediate release	5mg twice/thrice daily or 7.5mg thrice daily	3/38	5/38	0.60 (0.15; 2.34)	-0.05 (-0.19; 0.08)		
Dmochowski, 2002 <sup>276</sup>	Oxybutynin TDS	1.3mg	Oxybutynin TDS	2.6mg	1/130	0/133	3.07 (0.13; 74.65)	0.01 (-0.01; 0.03)		
Dmochowski, 2002 <sup>276</sup>	Oxybutynin TDS	1.3mg	Oxybutynin TDS	3.9mg	1/130	1/125	0.96 (0.06; 15.21)	0.00 (-0.02; 0.02)		
Dmochowski, 2002 <sup>276</sup>	Oxybutynin TDS	2.6mg	Oxybutynin TDS	3.9mg	0/133	1/125	0.31 (0.01; 7.62)	-0.01 (-0.03; 0.01)		
<b>Urinary retention</b>										
Corcos, 2006 <sup>270</sup>	Oxybutynin- controlled release	5mg/day	Oxybutynin- controlled release	10mg/day	2/77	8/77	0.25 (0.05; 1.14)	-0.08 (-0.15; 0.00)	-13 (-938; -6)	-78 (-155; -1)
Corcos, 2006 <sup>270</sup>	Oxybutynin- controlled release	5mg/day	Oxybutynin- controlled release	15mg/day	2/77	6/83	0.36 (0.07; 1.73)	-0.05 (-0.11; 0.02)		
Corcos, 2006 <sup>270</sup>	Oxybutynin- controlled release	10mg/day	Oxybutynin- controlled release	15mg/day	8/77	6/83	1.44 (0.52; 3.95)	0.03 (-0.06; 0.12)		
Davila, 2001 <sup>271</sup>	Oxybutynin transdermal	1.3mg	Oxybutynin- immediate release	5mg twice/thrice daily or 7.5mg thrice daily	9/38	13/38	0.69 (0.34; 1.42)	-0.11 (-0.31; 0.10)		
<b>Impaired urination</b>										
Davila, 2001 <sup>271</sup>	Oxybutynin transdermal	1.3mg	Oxybutynin- immediate release	5mg twice/thrice daily or 7.5mg thrice daily	9/38	9/38	1.00 (0.45; 2.24)	0.00 (-0.19; 0.19)		
Anderson, 1999 <sup>391</sup>	CR- oxybutynin	5 to 30mg once daily	IR-oxybutynin	5mg 1 to 4 times daily	13/53	15/52	0.85 (0.45; 1.61)	-0.04 (-0.21; 0.13)		
<b>Somnolence</b>										
Dmochowski, 2002 <sup>276</sup>	Oxybutynin TDS	1.3mg	Oxybutynin TDS	2.6mg	1/130	0/133	3.07 (0.13; 74.65)	0.01 (-0.01; 0.03)		
Dmochowski, 2002 <sup>276</sup>	Oxybutynin TDS	1.3mg	Oxybutynin TDS	3.9mg	1/130	2/125	0.48 (0.04; 5.24)	-0.01 (-0.03; 0.02)		

**Appendix Table F51. Clinical outcomes after oxybutynin treatments (individual RCTs) (continued)**

Reference	Active drug	Dose	Control drug	Dose	Active events/ randomized	Control events/ randomized	Relative risk (95% CI)	Absolute risk difference (95% CI)	Number needed to treat (95% CI)	Attributable events (95% CI)
Dmochowski, 2002 <sup>276</sup>	Oxybutynin TDS	2.6mg	Oxybutynin TDS	3.9mg	0/133	2/125	0.19 (0.01; 3.88)	-0.02 (-0.04; 0.01)		
Corcos, 2006 <sup>270</sup>	Oxybutynin- controlled release	5mg/day	Oxybutynin- controlled release	10mg/day	4/77	3/77	1.33 (0.31; 5.76)	0.01 (-0.05; 0.08)		
Corcos, 2006 <sup>270</sup>	Oxybutynin- controlled release	5mg/day	Oxybutynin- controlled release	15mg/day	4/77	2/83	2.16 (0.41; 11.44)	0.03 (-0.03; 0.09)		
Corcos, 2006 <sup>270</sup>	Oxybutynin- controlled release	10mg/day	Oxybutynin- controlled release	15mg/day	3/77	2/83	1.62 (0.28; 9.42)	0.01 (-0.04; 0.07)		
Davila, 2001 <sup>271</sup>	Oxybutynin transdermal	1.3mg	Oxybutynin- immediate release	5mg twice/thrice daily or 7.5mg thrice daily	7/38	14/38	0.50 (0.23; 1.10)	-0.18 (-0.38; 0.01)		
Anderson, 1999 <sup>391</sup>	CR- oxybutynin	5 to 30mg once daily	IR-oxybutynin	5mg 1 to 4 times daily	20/53	21/52	0.93 (0.58; 1.51)	-0.03 (-0.21; 0.16)		
Anderson, 1999 <sup>391</sup>	CR- oxybutynin	5 to 30mg once daily	IR-oxybutynin	5mg 1 to 4 times daily	20/53	21/52	0.93 (0.58; 1.51)	-0.03 (-0.21; 0.16)		
<b>Tachycardia</b>										
Salvatore, 2005 <sup>371</sup>	Oxybutynin	2.5 twice daily	Oxybutynin	5mg nocte	0/27	1/39	0.48 (0.02; 11.27)	-0.03 (-0.10; 0.05)		
<b>Urinary tract infection</b>										
Corcos, 2006 <sup>270</sup>	Oxybutynin- controlled release	5mg/day	Oxybutynin- controlled release	10mg/day	8/77	9/77	0.89 (0.36; 2.18)	-0.01 (-0.11; 0.09)		
Corcos, 2006 <sup>270</sup>	Oxybutynin- controlled release	5mg/day	Oxybutynin- controlled release	15mg/day	8/77	13/83	0.66 (0.29; 1.51)	-0.05 (-0.16; 0.05)		
Corcos, 2006 <sup>270</sup>	Oxybutynin- controlled release	10mg/day	Oxybutynin- controlled release	15mg/day	9/77	13/83	0.75 (0.34; 1.65)	-0.04 (-0.15; 0.07)		
<b>Vasodilatation</b>										
Chancellor, 2001 <sup>255</sup>	ER- oxybutynin	10mg/day	IR-oxybutynin	5mg/day	0/36	0/36	0.00 (0.00; 0.00)	0.00 (-0.05; 0.05)		

**Appendix Table F51. Clinical outcomes after oxybutynin treatments (individual RCTs) (continued)**

Reference	Active drug	Dose	Control drug	Dose	Active events/ randomized	Control events/ randomized	Relative risk (95% CI)	Absolute risk difference (95% CI)	Number needed to treat (95% CI)	Attributable events (95% CI)
<b>Vision abnormal</b>										
Dmochowski, 2002 <sup>276</sup>	Oxybutynin TDS	1.3mg	Oxybutynin TDS	2.6mg	3/130	2/133	1.53 (0.26; 9.03)	0.01 (-0.03; 0.04)		
Dmochowski, 2002 <sup>276</sup>	Oxybutynin TDS	1.3mg	Oxybutynin TDS	3.9mg	3/130	0/125	6.73 (0.35; 129.03)	0.02 (-0.01; 0.05)		
Dmochowski, 2002 <sup>276</sup>	Oxybutynin TDS	2.6mg	Oxybutynin TDS	3.9mg	2/133	0/125	4.70 (0.23; 96.98)	0.02 (-0.01; 0.04)		
<b>Vomiting</b>										
Chancellor, 2001 <sup>255</sup>	ER- oxybutynin	10mg/day	IR-oxybutynin	5mg/day	1/36	2/36	0.50 (0.05; 5.27)	-0.03 (-0.12; 0.06)		